UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
SELLAS enters the last quarter of 2026 with $138.3 million of cash at June 30, a pivotal Phase 3 REGAL trial waiting on its 80th event and topline data from the first-line SLS009 Phase 2 trial guided for Q4 2026. On September 25 the company added preclinical SLS009 data in pancreatic-cancer organoids. No REGAL event count above 78 of 80 has been published, the latest dated count being 78 as of August 18 from licensing partner 3D Medicines, and event 80 starts the final-analysis process rather than revealing the result.
Editorial alignment: October 2, 2026. News, financial and market snapshots below retain their stated reference dates.
Get every Merlintrader report in real time on Telegram: join @merlintraderpub_com.
SELLAS guided in its August 11, 2026 Q2 report to topline data for the randomized 80-patient first-line SLS009 trial in the fourth quarter of 2026, with 28 patients enrolled as of August 10. No newer enrollment figure or calendar date has been published through October 2, 2026; the ClinicalTrials.gov record (NCT04588922, updated September 3, 2026) lists an estimated primary completion of December 30, 2026 for the broader Phase 1/2a study. The pivotal Phase 3 REGAL trial has its own event-driven trigger — see the binary-risk note below.
As of May 11, 2026 — the last count dated by SELLAS — 78 of the 80 pre-specified events had occurred in REGAL. SELLAS has filed nothing with the SEC since its August 11 Form 10-Q, its September 25 press release did not update the count, and licensing partner 3D Medicines reported 78 of 80 as of August 18. Event 80 triggers database lock, blinded review and unblinding; it does not reveal the result. With 29.58% of the float sold short at the September 15, 2026 settlement date (Finviz, read October 2), the price reaction to either disclosure is likely to be amplified by positioning as much as by the news itself.
Cash stood at $138.3 million at June 30, 2026, up from $71.8 million at year-end 2025, funded mainly by $82.9 million of warrant exercises, with no shares sold through the $150 million ATM as of the August Form 10-Q. REGAL sits close to its final-analysis trigger, with 78 of 80 events as of May 11. SLS009 produced a 46% overall response rate in 35 evaluable relapsed/refractory AML-MR patients at ASH 2025, its first-line trial is guided to Q4 2026 topline data, and on September 25 SELLAS reported pancreatic organoid data in which SLS009 alone induced 17.9% apoptosis in a daraxonrasib-resistant model, versus 2.8% for daraxonrasib.
REGAL remains blinded and binary: nobody outside the trial process knows which arm is performing better, and a slower event pace can reflect either arm. Short interest was 29.58% of the float at the September 15, 2026 settlement date. SLS009’s Phase 2 data are encouraging but not registrational, and the September 25 pancreatic results come from laboratory organoid models, not patients. The stronger balance sheet came with dilution: shares outstanding rose to 201.95 million by August 10, 2026 from 153.10 million at year-end 2025, and the $150 million ATM remains available.
Next confirmed catalyst: no announcement that REGAL has reached its 80th event. The last count dated by SELLAS is 78 of 80 as of May 11, 2026; the August 11 Q2 release says the trial is approaching the threshold, and licensing partner 3D Medicines reported 78 of 80 as of August 18. Neither party has announced event 80, database lock, unblinding or topline results through October 2, 2026.
What is new since September 3. On September 25 SELLAS reported that SLS009 was active in patient-derived pancreatic-cancer organoids, including a MYC-amplified model resistant to daraxonrasib, with posters presented on September 27 at the AACR Conference on Pancreatic Cancer. These are laboratory results. SELLAS has filed no SEC report since August 11, so cash ($138.3 million at June 30), the share count (201.95 million at August 10) and SLS009 first-line enrollment (28 of 80 at August 10) stay at their Form 10-Q dates, with topline guided to Q4 2026.
SELLAS is a late-stage oncology company with two AML assets: GPS (galinpepimut-S), a WT1-targeting immunotherapeutic in the pivotal Phase 3 REGAL trial, and SLS009 (tambiciclib), a selective CDK9 inhibitor. REGAL’s final analysis starts at the 80th event; SLS009’s first-line Phase 2 topline is guided to Q4 2026.
Cash reached $138.3 million at June 30 after $82.9 million of warrant exercises in the first half, with no ATM sales, while the share count rose to 201.95 million by August 10. SELLAS is better funded and more diversified than a year ago; REGAL remains blinded and binary.
In a MYC-amplified organoid model resistant to daraxonrasib, SLS009 at 200 nM induced 17.9% apoptosis versus 2.8% for daraxonrasib, and the combination 36.5%. Laboratory data only; the release gives no REGAL count and no AML readout.
SELLAS said three abstracts developed with the University of Wisconsin School of Medicine and Public Health were accepted for the AACR Conference on Pancreatic Cancer, September 25–28, 2026, in San Diego.
3D Medicines said it received full settlement of the arbitration costs and that the licence agreement remains valid. It also reported 78 of 80 events in the global 3D189 trial as of August 18, the same count SELLAS gave as of May 11.
SELLAS reported $138.3 million in cash at June 30, a $9.6 million quarterly net loss, 28 patients enrolled in the first-line SLS009 Phase 2 trial and no ATM sales. REGAL was described as approaching the pre-specified 80th event.
The full deep dive has the answer’s building blocks: cash, dilution, catalysts and risks, every figure sourced.
Free. No signup. You decide, we don’t recommend.
The bull case starts with REGAL. If GPS shows a statistically and clinically meaningful overall-survival benefit in AML patients in second complete remission, SELLAS could be revalued around a potential first-in-class immunotherapeutic in a setting with no approved maintenance standard. Positive data would open regulatory planning, a possible BLA and, plausibly, strategic interest from companies with hematology infrastructure. SLS009 would then become additive rather than defensive: a second AML program advancing behind a successful late-stage asset.
A second bull layer is financial: $138.3 million of cash at June 30, 2026, no ATM sales and company guidance that cash funds planned operations for at least twelve months from the Q2 filing give SELLAS room either to prepare regulatory and commercial work after a positive REGAL or to protect SLS009 after a negative one.
The bear case is equally direct. REGAL can miss statistical significance, show a benefit too small to matter clinically, produce subgroup ambiguity or raise safety questions. Because GPS is the lead value driver, a failed or ambiguous result would likely hit the shares hard, and SLS009 alone may not support the current event-driven valuation. Capital structure is the second bear layer: warrant exercises lifted the share count to 201.95 million by August 10, the ATM remains live, and a negative readout would make any future financing far more dilutive. Even a positive readout would bring new capital needs for manufacturing, regulatory work and launch preparation.
| Scenario | What it would likely mean | Main watch items |
|---|---|---|
| Bull case | REGAL shows a clear OS benefit; GPS becomes a credible regulatory-stage asset; SLS009 adds pipeline depth. | Hazard ratio and p-value, safety, FDA guidance, BLA timing, financing strategy. |
| Base case | REGAL outcome pending; SLS009 first-line topline in Q4 2026; balance sheet supports near-term execution. | Event 80 announcement, database lock, SLS009 data, cash use, ATM activity. |
| Bear case | REGAL fails or is ambiguous; attention shifts to SLS009 at a deeper discount. | Management explanation, remaining runway, SLS009 data quality, financing needs, dilution. |
The red flags are not hidden: SELLAS is pre-commercial, REGAL is binary, SLS009 is promising but not definitive, dilution has been material, and cancer immunotherapy outside the checkpoint class has a mixed record in randomized trials. These points do not invalidate the opportunity; they define it.
This reading rests on four claims: REGAL is close to its final-analysis trigger, the balance sheet funds SELLAS through both AML readouts without new equity so far, SLS009 is a credible second AML asset, and the 3D Medicines dispute is closed with the licence intact. Each of them could turn out to be wrong, and these are the observations that would show it.
None of these is a prediction. They are the observations that would make the reading above wrong, listed so that a reader can check them rather than take the reading on trust.
Next confirmed catalyst: no announcement that REGAL has reached its pre-specified 80th event. The last count dated by SELLAS is 78 of 80 as of May 11, 2026. The August 11 Q2 release says the company is approaching the threshold and will announce it when it occurs; on August 18, licensing partner 3D Medicines told the Hong Kong Stock Exchange that the global trial of 3D189, the Greater China designation for GPS, had accumulated 78 events against the 80-event target as of the date of its announcement, August 18, 2026. That is the most recent dated count in the public record, although it comes from the partner rather than from SELLAS. Neither party has announced event 80, database lock, unblinding or topline results through October 2, 2026.
The September 25 release in detail. SELLAS reported that researchers at the University of Wisconsin–Madison tested SLS009 (tambiciclib) in patient-derived organoid models of pancreatic ductal adenocarcinoma, focusing on MYC-amplified tumors, including a model resistant to the RAS inhibitor daraxonrasib (RMC-6236). With a 24-hour SLS009 exposure meant to approximate pharmacokinetics in patients and assessment at 72 hours, SLS009 at 200 nM induced 17.9% apoptosis versus 2.8% with daraxonrasib and 14.5% necrosis versus 2.7%; the two drugs together produced 36.5% apoptosis and 30.6% necrosis. A combination with the BET inhibitor ZEN3694 was described as synergistic, with sustained MYC suppression at sub-physiological ZEN3694 concentrations. The three posters (A036, B127 and B043) were presented on September 27 at the AACR Conference on Pancreatic Cancer in San Diego. Chief Development Officer Dragan Cicic called the findings encouraging preclinical evidence that CDK9 inhibition may enhance RAS-directed therapy.
These are laboratory results in organoids, not data from patients, and the release contains no REGAL event count and no AML clinical readout. Their value is directional: they support the plan, first stated on August 11, to prepare clinical development in pancreatic cancer with an academic institution, which has not yet been announced as a registered trial.
What did not change. SELLAS has filed no 8-K, 10-Q or registration statement since August 11, 2026 (EDGAR, checked October 2), so cash ($138.3 million at June 30), the share count (201.95 million at August 10) and SLS009 first-line enrollment (28 of 80 at August 10) remain at their Form 10-Q dates. The 3D Medicines arbitration closed on August 18 with the award paid in full. The ClinicalTrials.gov REGAL record was last updated on October 1, 2025 and still lists an estimated primary completion of December 2025, so the registry is not a guide to timing.
Core verification: SELLAS, September 25, 2026 · SELLAS Q2 2026 results (Exhibit 99.1) · Q2 2026 Form 10-Q · 3D Medicines (HKEX: 1244) announcement of August 18, 2026 · SELLAS filings on EDGAR
SELLAS Life Sciences Group is a late-stage oncology company built around two assets: galinpepimut-S, or GPS, a WT1-targeting immunotherapeutic in the pivotal Phase 3 REGAL study, and SLS009, or tambiciclib, a highly selective CDK9 inhibitor in AML. Both have a readout ahead. REGAL’s final analysis starts when the 80th event occurs; the last dated count is 78 as of May 11, 2026. SLS009’s randomized first-line Phase 2 trial, 28 of 80 patients enrolled as of August 10, is guided to topline data in Q4 2026.
The balance sheet is the clearest change of 2026. Cash reached $138.3 million at June 30 after $82.9 million of proceeds from 48.77 million warrant exercises in the first half, with no ATM sales. The share base rose to 201.95 million by August 10, so the improvement came with dilution. The September 25 pancreatic organoid data widen the SLS009 story but are preclinical. The framing stays balanced: SELLAS is better funded and more diversified than a year ago, while REGAL remains blinded and binary.
Lead catalystREGALPhase 3 GPS trial in AML CR2/CR2p; final analysis after 80 events. Official event status78 / 80Last count dated May 11, 2026; August 11 wording says “approaching” event 80. Cash position$138.3MCash and equivalents at June 30, 2026. Second pillarSLS00928 of 80 first-line AML patients enrolled at August 10; topline expected Q4 2026.Share of the register by holder type, on October 2, 2026.
Ownership percentages are market-data aggregations rather than company disclosures, and they lag the filings that feed them. This Finviz snapshot uses 201.92 million shares and a 199.70 million float; the Form 10-Q reports 201.95 million shares outstanding as of August 10. Read the chart as a lagging holder-type estimate, not a fully diluted ownership calculation.
Source: Finviz, pulled October 2, 2026.
SELLAS is headquartered in New York and describes itself as a late-stage clinical biopharmaceutical company focused on novel therapies for a broad range of cancers. In practice, the market values it through acute myeloid leukemia, because both lead programs are AML programs. GPS is in a pivotal Phase 3 survival study in AML patients who reached complete remission after second-line salvage therapy. SLS009 is being studied in relapsed/refractory AML and in newly diagnosed high-risk AML patients unlikely to benefit from standard azacitidine plus venetoclax.
GPS, licensed from Memorial Sloan Kettering Cancer Center, targets the Wilms Tumor 1 protein (WT1), which is overexpressed in several hematologic malignancies and solid tumors. It has been studied in AML, mesothelioma, multiple myeloma and other settings, but the defining question is whether REGAL provides the randomized, registrational evidence needed to make it an approvable product.
SLS009, licensed from GenFleet Therapeutics in 2022 for territories outside Greater China, changed the shape of the company. It addresses a different problem with a different mechanism: transcriptional survival signals in high-risk AML biology, including resistance to venetoclax. The two assets do not repeat one scientific bet; they cover different stages of the disease. SELLAS has no marketed product, so its value rests on readouts, regulatory probability, financing flexibility and execution, which is why event-count updates, conference abstracts and warrant exercises move the shares.
The SELLAS story began with GPS and the idea that WT1, overexpressed in many cancers but scarcely present in most normal adult tissue, could be an immunotherapy target. Over time the market narrowed its attention to the program closest to a decisive catalyst: GPS in AML. REGAL was designed to test it in patients in second complete remission who are not proceeding to transplant, a group in which remission after salvage therapy does not equal cure and relapse risk stays high.
REGAL completed enrollment in 2024; the ClinicalTrials.gov record lists 127 patients. The study is event-driven, with the final analysis after 80 deaths. In August 2025 the Independent Data Monitoring Committee recommended that it continue without modification, a safety and futility milestone rather than a declaration of efficacy. On December 29, 2025 SELLAS reported 72 events as of December 26, below the 80 it had expected by year-end. Traders read the slower pace as a possible sign of longer survival on GPS; the narrower reading is that it is compatible with that hypothesis without proving it. On May 12, 2026 SELLAS reported 78 events as of May 11, leaving two to the trigger.
In parallel, SLS009 turned the company into a two-asset AML story. CDK9 regulates transcription of short-lived survival proteins such as MCL-1, a known route of resistance to venetoclax. At ASH 2025 SELLAS reported that SLS009 plus azacitidine and venetoclax achieved a 46% overall response rate in 35 evaluable relapsed/refractory AML-MR patients previously treated with venetoclax-based regimens, including 29% CR/CRi, with median overall survival of 8.9 months in the least pretreated cohort. Those results supported expansion into newly diagnosed high-risk AML, where the first patient was enrolled in March 2026, and in 2026 the company added preclinical work in pancreatic cancer.
US$ millions, as filed with the SEC. For a company without product revenue this is the line that describes the quarter.
Quarters not disclosed on their own are the arithmetic residual of the cumulative figures. Spending moves with trial phase, enrolment and manufacturing, so a single quarter is not a run rate.
Source: SEC XBRL company facts for SLS, tag ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost, read August 27, 2026.
REGAL is a randomized Phase 3 study of GPS versus investigator’s choice of best available therapy as maintenance in AML patients who reached complete remission after second-line salvage therapy (CR2/CRp2). The primary endpoint is overall survival, and the final analysis is triggered by the 80th event, meaning death. Overall survival is among the hardest and most meaningful endpoints in oncology, but event-driven timing is not under the company’s control, which is why the count has become a market variable in its own right.
The population matters. Remission after salvage therapy is clinically meaningful, yet it usually follows aggressive disease and prior treatment failure, and patients who do not proceed to transplant have no approved maintenance standard. GPS is meant to stimulate immune recognition of WT1-expressing leukemic cells and keep pressure on residual disease after remission. The challenge is historical: cancer vaccines and immunotherapeutics outside the checkpoint class have often failed to produce decisive randomized results, and REGAL is the trial built to separate hypothesis from proof.
Key interpretation: 78 of 80 events places REGAL very close to the final-analysis trigger. It does not reveal which arm is doing better. SELLAS remains blinded, and no one outside the formal trial process can know the outcome before unblinding.
Management has argued its case in public. In a July 9 LinkedIn post, CEO Angelos Stergiou rejected the reading that a delayed 80th event means the control arm is outperforming, noting that the CR2 maintenance setting has no approved standard therapy and arguing that slower event accrual is compatible with a durable effect on the active arm. In a later July communication he said SELLAS was still approaching the threshold, had entered a quiet period on specific clinical updates and was preparing database lock and BLA/CTD regulatory work. These are executive interpretations and prudent operational preparations, not unblinded evidence.
After event 80 the sequence is database lock, blinded data review, statistical analysis, unblinding and topline disclosure, so the trigger and the answer are separate announcements. The bull reading rests on the IDMC continuation recommendation, the longer-than-expected timeline, the unmet need and earlier clinical rationale. The bear reading is that a longer timeline can also reflect better survival in both arms, patient mix or chance, and that a study can take longer and still fail. A miss would not erase SLS009, but it would damage the near-term story and financing options.
SLS009 is what makes SELLAS more than a one-trial setup. CDK9 drives transcription of short-lived proteins that cancer cells depend on, and one of the most discussed in AML is MCL-1, often linked to resistance to venetoclax. Venetoclax plus azacitidine is the standard backbone for patients unfit for intensive chemotherapy, but many relapse or become refractory, and outcomes after venetoclax failure are poor. If resistance involves a shift from BCL-2 dependence toward MCL-1, a selective CDK9 inhibitor that suppresses those survival signals has a clear rationale. SELLAS has reported reductions in MCL-1 and survivin in AML cell lines and activity in adverse-risk subtypes.
The ASH 2025 data drove the reappraisal. In relapsed/refractory AML-MR patients previously treated with venetoclax-based regimens, SLS009 plus azacitidine and venetoclax produced a 46% overall response rate among 35 evaluable patients, including 29% CR/CRi, with response rates of 48% in ASXL1-mutated and 57% in TP53-mutated patients and no dose-limiting toxicities or treatment-related deaths in the reported dataset. Median overall survival reached 8.9 months in the least pretreated cohort and had not been reached in patients with one prior line. The study was small and not randomized, response does not always translate into survival, and cross-trial comparisons are fragile; the signal was nonetheless strong enough to justify earlier-line development.
The randomized first-line Phase 2 trial is designed for 80 newly diagnosed patients across a predictive-biomarker cohort and an early venetoclax-resistance cohort identified through transcriptomic, genomic and proteomic models. The Q2 Form 10-Q reports 28 patients enrolled as of August 10, 2026, with topline data expected in Q4 2026. The ClinicalTrials.gov record cited by SELLAS (NCT04588922, updated September 3, 2026) lists an estimated primary completion of December 30, 2026 for the broader Phase 1/2a study. An IMPACT-AML agreement extends the program through a European clinical network. Moving earlier in the disease is more competitive but potentially more valuable than a narrow salvage setting.
The pancreatic branch is newer. After describing single-agent activity in PDAC cells resistant to leading RAS inhibitors on August 11, SELLAS quantified it in patient-derived organoids on September 25 (section 01). Resistance to RAS inhibitors is a growing problem in pancreatic cancer, which explains the interest, but organoid activity does not establish efficacy in patients; the next verifiable milestone would be a registered clinical trial.
The bear case is that SLS009 remains early. CDK9 inhibition has attracted interest for years, and tolerability, dosing, selectivity and durability have been recurring problems across the class. SELLAS argues that SLS009 is differentiated on selectivity and tolerability; larger datasets, starting with the Q4 2026 first-line topline, will have to show it.
SELLAS had $138.3 million in cash and cash equivalents at June 30, 2026, up from $71.8 million at December 31, 2025. The company first gave the figure as a preliminary, unaudited estimate in a Form 8-K filed on July 27 and confirmed it in the Q2 report on August 11. The increase came mainly from warrant exercises: in the first half, holders exercised 48.77 million warrants for approximately $82.9 million, at a weighted-average exercise price of $1.70.
Q2 R&D expense was $6.3 million versus $3.9 million a year earlier, and G&A was $4.4 million versus $3.0 million. Interest income of $1.0 million, up from $0.3 million, offset part of the increase, leaving a quarterly net loss of $9.6 million, or $0.05 per share, against $6.6 million and $0.07 a year earlier. First-half R&D was $11.4 million and the first-half net loss $18.0 million. Net cash used in operating activities was $16.4 million in the first half, almost unchanged year over year.
The 10-Q attributes the first-half R&D increase mainly to $2.3 million of higher GPS manufacturing costs, $0.8 million of added clinical and regulatory consulting, $0.4 million of higher GPS trial costs and $0.4 million of higher SLS009 trial costs, and management expects R&D to keep rising as it prepares a potential GPS BLA and advances first-line SLS009. That preparation is rational, but a BLA still depends on positive REGAL results and FDA agreement.
The arbitration with 3D Medicines is now accounted for. The July 27 Form 8-K states that the July 24 decision dismissed SELLAS’ claims and allocated approximately $1.0 million of 3D Medicines’ costs to SELLAS; the 10-Q splits it into about $0.7 million of legal fees and $0.3 million of arbitrator and HKIAC costs, and the full approximately $1.0 million was recognized in Q2 G&A. The 8-K adds that $191.5 million of potential future milestones remained under the licence as of March 31, 2026, including the $13.0 million that had been in dispute, and the 10-Q gives the same $191.5 million at June 30, 2026. Those milestones are variable, outside SELLAS’ control and not revenue.
The per-share cost is visible. Common shares outstanding rose from 153.10 million at year-end 2025 to 201.95 million at August 10. At June 30, 2.65 million options, 3.33 million RSUs and 18.94 million shares reserved for future grants sat alongside the 9.71 million remaining warrants. The 10-Q states that no shares had been sold through the $150 million ATM, and no later SEC filing reports a sale through October 2, 2026.
| Metric | Latest reported figure | Interpretation |
|---|---|---|
| Cash and cash equivalents | $138.3M at June 30, 2026 | Several years of runway at the first-half pace (Merlintrader calculation). |
| H1 operating cash use | $16.4M | The relevant cash-burn measure, distinct from net loss. |
| H1 warrant exercises | 48.77M warrants; $82.9M proceeds | Main driver of both the cash balance and the larger share base. |
| Shares outstanding | 201.95M at August 10 | Post-quarter count from the Form 10-Q cover. |
| Warrants outstanding | 9.71M at June 30 | Residual equity-linked dilution after the first-half exercise wave. |
| ATM facility | Up to $150M; no sales reported | Flexibility that is also potential future dilution. |
| Arbitration charge | Approximately $1.0M in Q2 | Booked in G&A; the award was paid in full by August 18. |
SELLAS says current cash funds planned operations for at least twelve months from the issuance of the Q2 statements. At the first-half pace of operating cash use, $138.3 million would last several years, a Merlintrader calculation that assumes flat spending, which management does not expect as BLA preparation and SLS009 enrollment add costs.
SELLAS is led by founder, President and Chief Executive Officer Angelos M. Stergiou, M.D., Sc.D. h.c., who previously co-founded Genesis Life Sciences, a health-economics, pricing-reimbursement and market-access company. That background matters because, if REGAL is positive, the next problems are regulatory, access, pricing and manufacturing decisions. The team includes Dragan Cicic, M.D., Senior Vice President and Chief Development Officer; John T. Burns, C.P.A., Senior Vice President and Chief Financial Officer; Andrew Elnatan, Senior Vice President of Regulatory Affairs, CMC and Quality; and Stacy E. Yeung, Vice President, General Counsel and Corporate Secretary. Regulatory and CMC leadership is what turns a positive trial into a credible filing.
On the constructive side, SELLAS completed REGAL enrollment, passed the IDMC review, kept reporting the event count as the timeline moved, strengthened the balance sheet without using the ATM, presented SLS009 data at ASH, started first-line SLS009 enrollment, signed IMPACT-AML and added pancreatic preclinical work. On the skeptical side, it has a long history of financing needs and heavy dilution, it lost the 3D Medicines arbitration in July, and its valuation depends on future events. In June, stockholders approved 20 million additional shares under the 2023 Equity Incentive Plan, and the company amended executive severance and change-of-control arrangements for the CEO, CFO and Chief Development Officer, a governance item that is not evidence of a transaction.
The real test lies ahead: precise communication around a blinded trial now, and capital allocation after the data, in either direction.
| Period | Development | Reading |
|---|---|---|
| Pre-2022 | GPS developed as a WT1-targeting immunotherapeutic licensed from Memorial Sloan Kettering and studied across several tumor settings. | Scientific foundation of the lead asset. |
| March 2022 | SELLAS licensed GFH009, later SLS009/tambiciclib, from GenFleet Therapeutics outside Greater China. | Created the second pillar of the pipeline. |
| Q1 2024 | REGAL enrollment completed. | Moved the pivotal study into event-driven follow-up. |
| August 2025 | IDMC recommended that REGAL continue without modification. | Kept the pivotal thesis alive without proving efficacy. |
| October 2025 | R&D Day on AML, REGAL and SLS009. | Repositioned SELLAS as a broader AML story. |
| December 2025 | SLS009 plus AZA/VEN Phase 2 data at ASH 2025 in relapsed/refractory AML-MR: 46% ORR in 35 evaluable patients. | Made SLS009 a credible second asset. |
| December 29, 2025 | 72 REGAL events as of December 26; study still blinded. | Extended timing speculation; no outcome disclosed. |
| March 2026 | $71.8M cash at year-end 2025 reported; first patient enrolled in the newly diagnosed AML SLS009 trial. | Liquidity improving; second pillar advancing. |
| May 12, 2026 | 78 REGAL events as of May 11; $107.1M cash at March 31; about $44.1M of Q1 warrant proceeds. | REGAL two events from the trigger. |
| June 2, 2026 | 8-K: about $28.7M of warrant proceeds in April and May; 196,632,574 shares outstanding. | More liquidity, larger equity base. |
| June 16–18, 2026 | Annual Meeting; stockholders approved a 20,000,000-share increase under the 2023 Equity Incentive Plan. | Governance and dilution capacity, not a clinical catalyst. |
| June 24, 2026 | 8-K: amended severance and change-of-control arrangements for the CEO, CFO and Chief Development Officer. | Governance item; not evidence of a transaction. |
| July 9 and July 20–24, 2026 | CEO posts defend the 80-event design, then describe REGAL as approaching event 80, a quiet period and database-lock and BLA/CTD preparation. | Communication, not an event-80 announcement or efficacy data. |
| July 24–27, 2026 | Arbitrator dismissed SELLAS’ claims against 3D Medicines; SELLAS’ July 27 8-K reports an approximately $1.0M cost allocation and a preliminary $138.3M June 30 cash estimate; 3D Medicines said the licence remains in force. | Adverse legal result with limited financial cost; licence intact. |
| July 31 and August 7, 2026 | Schedule 13G filings: Vanguard Capital Management 9,666,278 securities (5.19%, held as warrants); State Street Corporation 12,996,558 shares (7%), both as of June 30. | Passive institutional holdings; not transaction evidence. |
| August 11, 2026 | Q2 results and Form 10-Q: $138.3M cash, $9.6M net loss, 28 first-line SLS009 patients, REGAL approaching event 80, no ATM sales. | Stronger liquidity; REGAL status unchanged. |
| August 18, 2026 | 3D Medicines told HKEX the arbitration award was paid in full, the licence remains valid, and the 3D189 global trial had accumulated 78 of 80 events as of that date. | Closes the cost order; the latest dated event count, from the partner rather than SELLAS. |
| September 2, 2026 | Three SLS009 preclinical pancreatic-cancer abstracts accepted at the AACR Conference on Pancreatic Cancer. | Conference disclosure; no clinical result. |
| September 25, 2026 | Organoid data: 17.9% apoptosis with SLS009 versus 2.8% with daraxonrasib in a resistant MYC-amplified model; 36.5% with the combination; posters presented September 27. | Preclinical support for a possible pancreatic program; no REGAL update. |
SELLAS has the ownership profile of a catalyst-sensitive small-cap biotech: index funds, warrant holders, event-driven funds, options traders and a large retail following all react to the same binary event. Two passive Schedule 13G filings add real data points, and both have to be read from the filings themselves.
Vanguard Capital Management filed on July 31, reporting 9,666,278 securities, or 5.19% of the class as of June 30, 2026, with 1,400,173 shares of sole voting power; the filing states that the reported holdings are in the form of warrants. State Street Corporation filed on August 7, reporting 12,996,558 shares, or 7% of the class as of June 30, with shared voting power over 12,677,559 shares and shared dispositive power over all of them. Both are Rule 13d-1(b) filings by institutions holding in the ordinary course, without a control purpose.
Ownership reading: large index-fund holders are a normal consequence of a market capitalization in the billions and of index membership; Finviz lists SLS in the Russell 2000. These filings are not evidence of open-market conviction buying, access to unblinded data or an acquisition.
Market-data aggregates read on Finviz on October 2, 2026 show institutional ownership of 36.72% and insider ownership of 1.11%. Short interest was 59.07 million shares, or 29.58% of a 199.70 million-share float, at the September 15, 2026 settlement date, up from 57.93 million at August 31. Finviz’s consensus target of $32.50 is an aggregate of third-party estimates. Third-party news reports said Alliance Global raised its target to $25 from $10 on July 6 and Maxim Group to $30 from $10 on July 8, both keeping Buy ratings; these are scenario-dependent opinions on a blinded trial and can change sharply after REGAL data.
Retail sentiment remains intense. On October 2, 2026, Stocktwits showed 90.98% of sentiment-tagged messages as bullish, while its normalized sentiment score was 47, labeled neutral, with 62,147 users watching the stream. The tagged subset is one-sided; the broader normalized signal is not. Dominant themes are event-80 timing, the theory that slower deaths mean benefit on the active arm, buyout speculation and the institutional filings. These are opinions of retail traders and non-professional investors, not evidence.
SELLAS sits in an information vacuum that produces rumors almost automatically: the trial is close to a mechanical trigger, management is in a quiet period on clinical specifics, executive contracts contain change-of-control language, and new institutional filings keep appearing. Each fact can feed a plausible story; plausibility is not confirmation. The table separates confirmed facts, reasonable inference and unsupported rumor, with the status checked against SELLAS releases and SEC filings through October 2, 2026.
| Market narrative | Evidence check | Status | What would confirm it |
|---|---|---|---|
| Event 80 has already occurred. | A third-party report in late August claimed it had; SELLAS has not announced it, and no release or filing through October 2 says so. | Unverified | A SELLAS announcement or filing. |
| The quiet period means database lock is complete. | The CEO referred to database-lock preparation, not a completed lock. | Unsupported inference | Company confirmation of event 80 and lock. |
| Topline will arrive on a specific date. | No date published; the process is event-driven and has post-event steps. | Timing rumor | Formal guidance with a dated window. |
| A named Big Pharma buyer is negotiating. | No merger filing, agreement or official announcement found. | Pure M&A rumor | An 8-K or joint press release. |
| The June change-of-control amendments prove a sale. | The amendments are real; such provisions are common retention planning. | Fact plus speculation | Separate transaction evidence. |
| Vanguard or State Street bought because REGAL is positive. | Both filed passive 13Gs; Vanguard’s holding is in warrants. | Contradicted by filings | A 13D or other evidence of strategic intent. |
| The pancreatic data are a clinical result. | The September 25 data come from patient-derived organoids in the laboratory. | Incorrect | A registered trial and patient data. |
| The arbitration terminated the Greater China licence. | 3D Medicines said on July 27 and August 18 that the licence remains valid and in force. | Contradicted | A termination notice or contrary SELLAS disclosure. |
| The arbitration had no financial effect. | The Q2 10-Q records an approximately $1.0 million charge. | Incorrect | Already confirmed in the 10-Q. |
Rumor rule for this coverage: no acquisition claim, readout date, hidden-data theory or outcome prediction is treated as fact unless a SELLAS filing, a company press release, a regulatory source or another directly attributable primary document supports it. A company this close to an event-driven final analysis should prepare database-lock workflows, regulatory documents and financing options before knowing the result; turning that prudence into proof of success is the mistake. Strategic optionality stays on the board, but until the disclosure standard changes, the buyout story belongs in the rumor box.
The first catalyst remains a formal SELLAS announcement that REGAL has reached the 80th event, a mechanical trigger rather than the efficacy result. The second is the post-event sequence ending in topline disclosure, where the decisive evidence will be the overall-survival hazard ratio, confidence interval and p-value, median survival if mature, the shape of the curves, subgroup consistency and safety.
The third catalyst is the first-line SLS009 Phase 2 topline, guided to Q4 2026. Enrollment stood at 28 of 80 on August 10, and the company has not said how many patients the topline will include; the useful measures are CR/CRi, duration, MRD if disclosed, survival, safety and whether the biomarker cohorts separate responders. The fourth is follow-through on pancreatic cancer after the September 25 organoid data: a named academic partner, a protocol or a trial registration would be the first clinical step. The fifth is capital: the Q3 Form 10-Q, normally due in November, will show how fast BLA preparation and trial spending consume the $138.3 million and whether any shares were sold through the ATM.
| Catalyst / watch item | Status as of October 2, 2026 | Evidence standard |
|---|---|---|
| REGAL 80th event | Not announced. 78/80 as of May 11 per SELLAS; 3D Medicines reported 78/80 as of August 18. | SELLAS press release or SEC filing. |
| REGAL topline | Not released. | Results release with statistical and safety detail. |
| SLS009 first-line AML topline | 28/80 enrolled at August 10; guidance Q4 2026. | SELLAS clinical disclosure or conference data. |
| SLS009 pancreatic program | Organoid data presented September 25–27; no clinical trial announced. | Trial registration or company announcement. |
| Cash, ATM, warrants | $138.3M at June 30; no ATM sales reported; 9.71M warrants at June 30. | Q3 2026 Form 10-Q or financing 8-K. |
| 3D Medicines licence | Award paid in full per the August 18 announcement; licence in force. | Any amendment or milestone disclosure. |
| M&A or partnership | No confirmed transaction. | Definitive agreement, 8-K or joint announcement. |
The capital structure changed fast in 2026, so ownership percentages move quickly and are best read through filings rather than snapshots. The largest disclosed warrant wave has already converted: 48.77 million warrants were exercised in the first half for $82.9 million, only 9.71 million remained at June 30, and the share count reached 201.95 million by August 10. SELLAS is better funded, and each share is a more diluted claim than at year-end 2025.
Insider ownership is small, about 1.11% on the Finviz aggregate of October 2, 2026, and management is compensated largely in equity, which is normal for a development-stage biotech. Form 4 filings, grants and any open-market purchases around REGAL deserve attention. The $150 million ATM should be watched without being exaggerated: unused as of the Q2 10-Q, it can be a rational funding tool after favorable data or an overhang if used into weakness. The documents that tell the real story are the 10-K and 10-Q, S-3 and ATM filings, financing 8-Ks, Form 4s and 13G/13D reports.
The strongest version of the story needs more than a headline that REGAL is positive: a clean overall-survival benefit, clearly separated Kaplan-Meier curves, a hazard ratio and p-value that leave little ambiguity, a safety profile suited to a vulnerable AML population, and a credible regulatory path with BLA, CMC and timing. It would get stronger again if first-line SLS009 shows response depth, durability and evidence that the biomarker strategy picks out patients who need more than AZA/VEN.
The story would weaken sharply if REGAL misses, forcing a revaluation around SLS009, cash and remaining optionality; an ambiguous result could be punished almost as hard. The second way it weakens is capital execution: aggressive raising at weak prices, poor communication around the ATM or dilution dominating the post-data narrative. The third is scientific overextension: a good SLS009 signal does not validate every CDK9 hypothesis, and organoid activity in pancreatic cancer is not a solid-tumor program yet. The fourth is the licence: the arbitration cost is settled, but the $191.5 million of variable Greater China milestones depends on development decisions SELLAS does not control.
SELLAS is a high-risk, high-catalyst biotech with more substance than a momentum trade. It has a pivotal Phase 3 survival trial waiting on its 80th event, a second AML program guided to topline data in Q4 2026, new preclinical pancreatic data, $138.3 million of cash at June 30 and no ATM sales reported. It also has a share count above 201 million, a lost arbitration and a rumor cycle that keeps running ahead of the verified record.
Three questions matter more than daily price noise. Can REGAL show a real survival benefit for GPS in AML CR2/CRp2? Can SLS009 become a credible AML program beyond a small relapsed/refractory dataset? Can management turn a stronger balance sheet into value-preserving execution rather than another dilution cycle? The catalyst is real and the science coherent, but event timing is not efficacy, social sentiment is not data, and a stronger balance sheet is not permanent de-risking.
The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.
Share of sentiment-tagged Stocktwits messages marked bullish, by day. The last column is the most recent reading.
These are self-reported tags from retail traders and non-professional investors, not analyst research. The series measures how crowded one side of the conversation has become, which is a description of the audience rather than of the company.
Source: Stocktwits public sentiment series for $SLS, read on August 9, 2026.
Follow the Merlintrader Trading Pub feed for verified catalyst updates, FDA and clinical-trial developments, new stock hubs and clearly labeled market rumors.
Join @merlintraderpub_com on TelegramSELLAS, September 2, 2026: three SLS009 preclinical posters accepted for the AACR Conference on Pancreatic Cancer, September 25–28, 2026.
Items that stood in the opening overview before the September 23, 2026 layout update, kept in full with their original dates.
Primary-source check through September 3, 2026: no new SEC filing (10-Q/8-K) has landed since the August 11, 2026 Form 10-Q, and neither SELLAS nor its licensing partner has reported a REGAL event count above the 78-of-80 figure confirmed May 11 and repeated August 18. The September 2 item below is a routine conference-abstract disclosure and does not change REGAL or SLS009 catalyst timing.
There is no date. REGAL is event-driven: the final analysis starts after the 80th event, and the last count dated by SELLAS is 78 of 80 as of May 11, 2026, and licensing partner 3D Medicines reported 78 as of August 18, 2026. SELLAS has said it will announce event 80 when it occurs; database lock, blinded review, statistical analysis and unblinding then come before topline results. No announcement had been made through October 2, 2026.
On September 25, 2026 SELLAS reported organoid data from the University of Wisconsin–Madison: in a MYC-amplified pancreatic-cancer model resistant to daraxonrasib, SLS009 at 200 nM induced 17.9% apoptosis versus 2.8% for daraxonrasib, and 36.5% in combination. These are preclinical results, not data from patients. Press release
Cash and cash equivalents were $138.3 million at June 30, 2026, up from $71.8 million at December 31, 2025, mainly from $82.9 million of warrant exercises. First-half operating cash use was $16.4 million, and the company says its cash funds planned operations for at least twelve months from the Q2 filing. Form 10-Q
SELLAS guides to topline data in the fourth quarter of 2026 from its randomized 80-patient Phase 2 trial in newly diagnosed AML, which had enrolled 28 patients as of August 10, 2026. No exact date has been announced.
On July 24, 2026 the sole arbitrator dismissed SELLAS’ claims and allocated about $1.0 million of 3D Medicines’ costs to SELLAS, recognized in Q2. On August 18, 3D Medicines said the award had been paid in full and that the Greater China licence remains valid; SELLAS reports $191.5 million of potential milestones remaining under it at June 30, 2026. Form 10-Q
The Form 10-Q reports 201.95 million shares at August 10, 2026, up from 153.10 million at year-end 2025, after 48.77 million warrants were exercised in the first half. At June 30, 9.71 million warrants remained, and the $150 million ATM had not been used.
Every Merlintrader stock hub, catalyst update and market brief is published to Telegram the moment it goes live. No paywall, no spam, just the research.
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $SLS or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.